German Health minister presents new draft of act to stabilise SHI fund finances
In March 2022, Lauterbach shared a non-authorized draft of his reform plans to stabilise the SHI funds finances. However, this draft version
German Market Access – Simplified
Everything you need to know in one place, explained in simple terms
In March 2022, Lauterbach shared a non-authorized draft of his reform plans to stabilise the SHI funds finances. However, this draft version
The Lauer Taxe is a database of all pharmaceutical entities, e.g. drugs, medical devices and also remedies, and their prices.
In this post, I am discussing the different types of prices, price discounts and rebates, and who is paying what.
Currently, in Germany, free pricing applies in the first year. This means, at the time of launch in the German market, pharmaceutical companies are free to set the price for their product with a new chemical entity (NCE). This price is then valid for the first 12 months from the day of launch.
On 6 December 2021, Prof. Dr. Karl Lauterbach was announced as the new German health minister. This might mean quite a lot